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Abstract: Medical castration using gonadotropin-releasing hormone (GnRH) receptor agonists 
currently provides the mainstay of androgen deprivation therapy for prostate cancer. Although 
effective, these agents only reduce testosterone levels after a delay of 14 to 21 days; they also 
cause an initial surge in testosterone that can stimulate the cancer and lead to exacerbation of 
symptoms (“clinical flare”) in patients with advanced disease. Phase III trial data for the recently 
approved GnRH receptor blocker, degarelix, demonstrated that it is as effective and well tolerated 
as GnRH agonists. However, it has a pharmacological profile more closely matching orchiectomy, 
with an immediate onset of action and faster testosterone and PSA suppression, without a 
testosterone surge or microsurges following repeated injections. As a consequence, with this 
GnRH blocker, there is no risk of clinical flare and no need for concomitant antiandrogen flare 
protection. Degarelix therefore provides a useful addition to the hormonal armamentarium for 
prostate cancer and offers a valuable new treatment option for patients with hormone-sensitive 
advanced disease. Here, we review key preclinical and clinical data for degarelix, and look at 
patient-focused perspectives in the management of prostate cancer.
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Introduction
The key role of testosterone in the growth of prostate cancer was first demonstrated 
back in 1941 by Huggins and Hodges;1 since then, androgen deprivation therapy (ADT) 
has provided the mainstay of treatment for patients with hormone-sensitive advanced 
prostate cancer. Because of its documented links with therapeutic efficacy, testosterone 
suppression is now an accepted endpoint in prostate cancer clinical trials and has been 
used as a surrogate endpoint during the approval of several hormonal treatments.2 
Prostate-specific antigen (PSA) is currently widely-used in prostate cancer screening 
and this marker can also be helpful in monitoring treatment response, disease recurrence 
and potentially in providing evidence of disease progression during prostate cancer 
ADT.3,4 Testosterone production is regulated by two key hormones: gonadotropin-
releasing hormone (GnRH) and luteinizing hormone (LH). GnRH is secreted from 
the hypothalamus in a pulsatile manner and binds to high-affinity cell surface recep-
tors in the pituitary gland, activating a chain of events that lead to synthesis and 
secretion of LH and follicle-stimulating hormone (FSH).5 LH stimulates testosterone 
production and secretion by the Leydig cells of the testes. Bilateral orchiectomy was 
the first ADT approach used in prostate cancer therapy and rapidly reduces circulat-
ing testosterone levels.6 Although effective, its irreversibility and associated adverse 
psychological effects are often unacceptable to patients and so, with the advent of Cancer Management and Research 2010:2 40
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newer pharmacological approaches to ADT, orchiectomy is 
now used much less frequently.
GnRH receptor agonists were first introduced in the 1980s 
and are currently the most commonly used ADT in prostate 
cancer.7 These agents act on the hypothalamic–pituitary–
gonadal (HPG) axis via a negative feedback mechanism.8 
Binding of a GnRH receptor agonist to the GnRH receptor 
initially triggers the secretion of LH, which in turn causes 
a surge in testosterone production lasting 1 to 2 weeks.9,10 
This may stimulate prostate cancer cells, and in patients with 
advanced disease, exacerbate clinical symptoms such as skeletal 
pain, ureteral obstruction and spinal cord compression, which 
may lead to paralysis and, in rare cases, death.11,12 The clinical 
effects of flare can be limited by concomitant antiandrogen 
treatment (eg, flutamide or bicalutamide),13 which acts to inhibit 
the stimulatory effect of the testosterone surge by blocking 
testosterone binding to androgen receptors in prostate cancer 
cells. However, this strategy is not always effective and antian-
drogens are also associated with additional side effects.14,15
Chronic administration of GnRH receptor agonists 
eventually leads to suppression of LH, which results in a 
reduction of testosterone release. However, GnRH agonists 
may also induce “microsurges” of LH and testosterone 
after each re-injection.16,17 Overall, 22.6% of patients in the 
Zinner et al study17 had a testosterone surge on at least one 
repeat injection; this comprised 18.6% of patients receiving 
goserelin 10.8 mg and 27.9% of those receiving goserelin 
3.6 mg depots. No symptoms of clinical flare were reported 
at the time of surge for any of the patients experiencing a 
testosterone surge in this study. In a separate study looking 
at the potential for agonistic stimulation during leuprolide 
treatment, 5.9% and 2.9% of patients receiving leuprolide 
monthly depot had testosterone increases to 0.5 ng/mL 
after the second and third injection, respectively.16 In a 
further study of 73 patients receiving GnRH agonist treat-
ment, overall, 56.2% of patients had breakthrough increases 
in testosterone of 20 ng/mL, with increases 50 ng/mL 
occurring in 24.7% of patients.18 In contrast to the results of 
Zinner et al, a significant association was shown between 
testosterone increases and clinical outcome in terms of 
PSA progression, demonstrating the importance of keeping 
testosterone levels low during ADT. The effects were most 
notable the higher the testosterone breakthrough threshold 
breached. Further analysis of data from this trial showed that 
patients who maintained their testosterone levels consistently 
below 32 ng/mL had significantly longer PSA progression-
free survival compared with those having any breakthrough 
increases above this threshold (137 months vs 88 months, 
respectively; P  0.03).18 A more recent report of data from 
129 men with previously untreated prostate cancer and bone 
metastases demonstrated that risk of death significantly 
correlated (P  0.05) with the 6-month serum testosterone 
level achieved during goserelin treatment.19 The authors 
concluded that based on their results, lowering testosterone 
levels as much as possible should be the goal of ADT in 
patients with metastatic prostate cancer.
Other pharmacological endocrine options for prostate 
cancer include the use of estrogens, antiandrogen monother-
apy, and complete androgen blockade using an antiandrogen 
plus a GnRH receptor agonist.7 However, these approaches 
are used infrequently in practice due to concerns about 
efficacy and/or side effects, which can include cardiotoxic-
ity, gynecomastia, breast pain and liver toxicity.7 The need 
exists, then, for additional effective and well-tolerated treat-
ment options for patients with advanced, hormone-sensitive 
prostate cancer.
Degarelix: a new GnRH receptor 
blocker
The testosterone surge and clinical flare associated with GnRH 
agonists led to research into new GnRH analogues that blocked 
the GnRH receptor directly, thus obviating these agonist-
associated problems. GnRH receptor antagonists (blockers) 
are a new class of endocrine therapy that bind directly to the 
GnRH receptor, rapidly blocking the release of both LH and 
FSH, and thereby reducing testosterone secretion (Figure 1).20–25 
In contrast to the agonists, GnRH antagonists do not cause 
an initial stimulation of LH production, and therefore do not 
cause testosterone surge or clinical flare.12 Abarelix was the 
first GnRH antagonist to be licensed for prostate cancer treat-
ment; however, this agent was associated with immediate-onset 
systemic allergic reactions resulting from histamine release, 
and so is currently marketed only in Germany.26
Degarelix is a new GnRH receptor blocker that has recently 
been approved for the treatment of men with advanced, 
hormone-sensitive prostate cancer.27 It acts by immediate and 
competitive blockade of GnRH receptors in the pituitary; like 
other GnRH antagonists, degarelix does not cause an initial 
stimulation of LH production via the HPG axis, and therefore 
does not cause testosterone surge or clinical flare.12
Pharmacology and 
pharmacokinetics of degarelix
Degarelix  (Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph 
(L-hydrorootyl)-D-4Aph (carbamoyl)-Leu-Ilys-Pro-D-Ala-
NH2) is a fully synthetic, linear decapeptide amide analogue Cancer Management and Research 2010:2 41
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of natural GnRH that contains seven unnatural amino acids, 
five of which are D-amino acids.28
Data from preclinical studies
The pharmacology of degarelix was initially assessed in 
various preclinical studies. In vitro radioligand binding assays 
demonstrated that degarelix has a high affinity to cloned human 
GnRH receptors expressed on COS-I cells, with a Ki value of 
1.68 ± 0.12 nM.29 Degarelix demonstrated similar functional 
antagonism to three other GnRH antagonists (azaline B, cetro-
relix and ganirelix) and showed no significant affinity towards 
other tested receptors. Data from in vitro metabolism studies 
suggest that degarelix is unlikely to be associated with any 
clinically significant drug–drug interactions.29
The in vivo effect of degarelix on tumor size was inves-
tigated in three experimental models of hormone-dependent 
prostate cancer. Antitumor effects were observed in androgen-
dependent human prostate tumors (PAC120) in nude mice and 
androgen-dependent rat prostate tumors (Dunning R-3327H) 
when degarelix was administered at a dose of 2 mg/kg every 
2 weeks or once a month, respectively. At the tested doses, 
degarelix reduced tumor volume with a similar efficacy to 
surgical castration.29 Degarelix had no effect on the growth of 
the androgen-independent human prostate tumor PC3.
The pharmacological profile of subcutaneous degarelix was 
originally assessed in rats and monkeys.25 Single subcutaneous 
injections in rats produced dose-dependent reductions in LH 
and testosterone levels and the duration of LH suppression 
was found to increase with dose. Degarelix fully suppressed 
LH and testosterone levels for more than 40 days after a single 
2 mg/kg subcutaneous injection in castrated and intact rats 
(Figure 2) as well as in ovariectomized rhesus monkeys. The 
testosterone suppression profile during degarelix treatment 
more closely matched that of orchiectomy compared with the 
other GnRH antagonists tested. Furthermore, degarelix showed 
a longer duration of action than abarelix, ganirelix, cetrorelix, 
and azaline B and demonstrated only weak histamine-releasing 
properties in vitro. A more recent study has confirmed that 
cetrorelix and abarelix are potent activators of human skin 
mast cells and that ganirelix is a less potent activator in terms 
GnRH blocker (antagonist)
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pituitary
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GnRH
Hypothalamus
Testis
FSH, LH
Testosterone
GnRH blocker
Prostate
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GnRH blockers have an immediate
onset of action, preventing gonadotropin
release through receptor blockade,
leading to rapid suppression of LH
and testosterone
Figure 1 Mode of action of GnRH receptor antagonists.58 Reproduced with permission from Anderson J. Degarelix: a novel gonadotropin-releasing hormone blocker for the 
treatment of prostate cancer. Future Oncol. 2009;5(4):433–443.58 Copyright © 2009 Future Medicine Ltd.
Abbreviations: GnRH, gonadotrophin-releasing hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone.Cancer Management and Research 2010:2 42
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of inducing histamine release.30 In the same study, degarelix 
had the lowest histamine-releasing potential, suggesting that it 
is the least likely agent to cause histamine-related immediate-
onset allergic reactions.
The pharmacological profile of degarelix was also assessed 
in male beagle dogs.31 In this study, administration conditions 
were varied with respect to route, dose, concentration and vol-
ume. The plasma concentration–time profile of subcutaneous or 
intramuscular degarelix was best described by a two-compart-
ment model, with two input functions to describe the rapid initial 
increase in the plasma levels, and the prolonged absorption pro-
file of degarelix. Intramuscular administration led to more rapid 
absorption of degarelix. The relative fraction absorbed varied 
with the concentration of the dosing solution; the absorbed frac-
tion was reduced by ∼50% when the concentration was increased 
from 1.25 to 40 mg/mL. The initial rate of absorption was also 
dependent on concentration, with slower absorption at higher 
concentrations. After subcutaneous administration, degarelix 
immediately forms a gel “depot” at the injection site, leading to 
sustained release of the drug into the circulation. Release from 
the depot was found to be dependent on the degarelix dose and 
the administration volume.32
Reconstitution and administration of degarelix
Reconstitution of the lyophilized degarelix powder involves 
addition of sterile water to the product vial followed by 
swirling to minimize production of foam. Recently, a study 
was performed to assess the time taken for reconstitution of 
two degarelix doses. It was found that average reconstitution 
times were 2.96 and 4.25 minutes for 80 and 120 mg degarelix 
doses, respectively (Ferring Pharmaceuticals, data on file). 
Virtually all (99%) of the 80 mg vials were reconstituted 
within 5 minutes compared with 72% of vials for the 120 mg 
dose (99% of which were reconstituted within 8 minutes) 
(Figure 3). The average concentration of degarelix in the 
reconstituted samples was 19.9 mg/mL for the 80 mg dose 
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Figure 2 Mean (n = 8; ± SeM) testosterone levels in the intact rat induced by degarelix, abarelix, azaline B, and ganirelix, administered at a dose of 2 mg/kg in 5% mannitol, 
compared with surgical castration. Reproduced with permission from Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL. Pharmacological profile of a new, potent, 
and long-acting gonadotropin-releasing hormone antagonist: degarelix.  J Pharmacol Exp Ther. 2002;301:95–102.25 Copyright © 2002 American Society for Pharmacology & 
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and 39.3 mg/mL for the 120 mg dose, confirming that the 
reconstitution process in all vials was adequate.
Degarelix is administered via subcutaneous injection into 
the abdominal subcutaneous fat surrounding the umbilicus.33 
The 240 mg starting dose is given as two 3 mL injections 
(final degarelix concentration of 40 mg/mL) and the 80 mg 
maintenance dose is given as a single 4 mL injection (final 
degarelix concentration of 20 mg/mL).
Data from clinical studies
The pharmacokinetics of degarelix were initially assessed in 
a phase I study in 36 healthy male volunteers.34 In this study, 
single doses of degarelix (1.5, 6.0, 15 or 30 µg/kg) were 
administered via 45-minute intravenous infusions, or a single 
dose of 20 mg was given intramuscularly or subcutaneously. 
As was seen in the early preclinical studies, degarelix naturally 
formed a depot at high concentrations (mg/mL) after both 
subcutaneous and intramuscular injection, which resulted in 
a longer half-life compared with intravenous injection. The 
pharmacokinetics of degarelix after subcutaneous injection 
were also found to be dose- and concentration-dependent, and 
bioavailability was estimated at 30% to 40% following both 
subcutaneous and intramuscular administration. Similar levels 
of LH, FSH and testosterone suppression were seen when 
degarelix was administered via the intravenous, subcutaneous 
or intramuscular routes.
Two further studies in prostate cancer patients assessed 
the effects of a single dose of degarelix, 120 to 320 mg given 
in various concentrations in the range of 12 to 27 mg/mL 
or subcutaneous degarelix administered in single initiation 
doses of 200 or 240 mg with maintenance doses of 80, 120 
or 160 mg. In a combined analysis of these studies, the effects 
of degarelix were again shown to be dose- and concentra-
tion-dependent; higher doses resulted in superior testosterone 
suppression, but lower concentrations of a given dose yielded 
better responses.35
In early single- and multiple-dose degarelix studies,29 
the mean terminal half-life was between 23 and 61 days 
with marked variability between patients and studies. Cmax 
and AUC were influenced by dose, number of injections 
and concentration and Tmax ranged between 34 and 62 hours. 
Steady-state plasma levels occurred after 5 to 6 months 
with the degarelix 240/80 mg regimen. Additional pharma-
cokinetic data relating to the subcutaneous administration 
of degarelix 240 mg at a concentration of 40 mg/mL were 
gained from the pivotal phase III trial (CS21).29 In this trial, 
the AUC0–28 days was 635 (602 to 668) days * ng/mL. Cmax 
was 66.0 (61.0 to 71.0) ng/mL and occurred at a Tmax of 
40 (37 to 42) hours. Mean trough values were 11 to 12 ng/mL 
after the starting dose and 11 to 16 ng/mL after maintenance 
dosing of 80 mg/month (at a concentration of 20 mg/mL). 
In humans, degarelix is subject to common peptiditic degra-
dation during passage through the hepatobiliary system and 
is mainly excreted as peptide fragments in the feces, with 
approximately 20% excreted unchanged in the urine.
Dose-finding studies of degarelix
Study designs and patients
Two phase II, degarelix dose-finding studies of similar 
overall design were performed in Europe (CS12)36 and 
North America (CS14)37 Both were open-label, randomized, 
parallel-group, 1-year studies including adult male patients 
with histologically confirmed prostate cancer (all stages), in 
whom hormonal treatment was indicated. Patients were ran-
domized to treatment with different degarelix dose regimens 
in these two studies. In CS12, 189 patients were randomized 
to one of six degarelix treatment groups: starter doses of 
either 200 or 240 mg followed by monthly maintenance doses 
of 80, 120, or 160 mg, all given via subcutaneous injection.36 
In CS14, 127 patients were randomized to one of two 
degarelix treatment groups: starter dose of 200 mg followed 
by monthly maintenance doses of either 60 or 80 mg, once 
again all given via subcutaneous injection.37
Efficacy data
In the European study, 88% and 92% of patients in the 200 and 
240 mg starter-dose groups, respectively, achieved testoster-
one levels 0.5 ng/mL by day 3, and there was no evidence 
of testosterone surge.36 The proportion of patients achieving 
castrate testosterone levels after 1 month of treatment was 
significantly higher for patients treated with a degarelix starter 
dose of 240 mg compared with those receiving a starter dose 
of 200 mg (95% and 86%; P = 0.048). The proportion of 
patients with castrate levels from month 1 until the end of 
the study also increased with increasing maintenance dose 
(Table 1). In this study, inadequate testosterone suppression 
resulted in withdrawal of 8.5% of patients, with 50% of all 
withdrawals occurring in the lowest dose group (200/80 mg). 
Median time to a 50% reduction in PSA was 14 days for all 
groups and the median time to a 90% reduction was 56 days for 
all groups except those receiving degarelix 200/80 mg, which 
took an average of 84 days. After 12 months of treatment, 
the median PSA reduction from baseline was 97% to 98%; 
overall, 7% of patients experienced PSA progression.36
In the North American study, 89% of patients overall 
achieved testosterone levels 0.5 ng/mL by day 3 and there Cancer Management and Research 2010:2 45
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was no significant difference between treatment groups and 
no evidence of testosterone surge.37 Somewhat surprisingly, 
after 1 month of treatment, there was a trend for improved 
testosterone control in the 60 mg maintenance dose group 
compared with the 80 mg group, with 93% and 83% of 
patients treated with these doses, respectively, achieving cas-
trate testosterone levels (P = 0.073). The proportion of patients 
with castrate levels at month 1 who also had castrate levels at 
the 1-year study visit was 93% and 98% in the 60 and 80 mg 
maintenance dose groups, respectively (Table 1). However, 
when early failures due to an inadequate starter dose were 
excluded, a maintenance dose of degarelix 80 mg appeared 
most effective in maintaining castrate testosterone levels to 
1 year (98% vs 93%, for 80 mg vs 60 mg, respectively). Simi-
lar to the European study, the median time to a 50% reduction 
in PSA was 14 days and the median time to 90% reduction 
was 56 days, in both treatment groups. After 12 months of 
treatment, the median PSA reduction from baseline was 96%; 
overall, 7% of patients experienced PSA progression.37
Safety and tolerability data  
from the phase II dose-finding studies
In both studies, degarelix treatment was well tolerated, with 
most adverse events being mild to moderate in intensity 
and related to the known effects of androgen deprivation; 
there were no immediate-onset systemic allergic reactions. 
Overall, 7%36 and 5%37 of patients in these trials withdrew 
due to adverse events.
Efficacy and safety conclusions  
from the phase II dose-finding studies
Data from these trials suggested that degarelix 240 mg 
appeared to be the optimal starter dose for evaluation in future 
studies, as this resulted in castrate testosterone levels in 90% 
of patients within 3 days.36 In contrast, inadequate suppres-
sion occurred with the use of a 200 mg starter dose used in 
the North American study.37 Two maintenance doses (80 mg 
and 160 mg) were also identified for future evaluation as no 
dose-dependent adverse events were noted in either study. In 
these studies, degarelix demonstrated effects on testosterone 
and PSA levels similar to those observed with orchiectomy.
Phase III comparative study
Study design and patients
A 1-year, multicenter, randomized, open-label, parallel-group, 
phase III trial (CS21) was conducted, which was designed to 
demonstrate the statistical noninferiority of degarelix versus 
the GnRH receptor agonist leuprolide.38 In this trial, patients 
with histologically confirmed prostate cancer (all stages), for 
whom ADT was indicated, were randomized to one of three 
treatment groups: degarelix (administered subcutaneously) at 
a starter dose of 240 mg followed by monthly maintenance 
doses of either 80 mg (240/80 group; n = 207) or 160 mg 
(240/160 group; n = 202), or monthly intramuscular injec-
tions of leuprolide depot 7.5 mg (n = 201). In the leuprolide 
group, antiandrogens could also be given as flare protection 
at the investigator’s discretion.
Efficacy data
Primary analyses
The primary analyses of data from the CS21 trial dem-
onstrated that both degarelix doses were noninferior to 
leuprolide for the primary endpoint (testosterone response: 
serum testosterone 0.5 ng/mL at all monthly measurements 
between days 28 and 364; Table 1).38 A treatment response 
was achieved by 97.2%, 98.3% and 96.4% of patients in the 
degarelix 240/80 mg, 240/160 mg and leuprolide groups, 
respectively. Degarelix resulted in a more rapid treatment 
response than leuprolide and median testosterone levels were 
significantly lower in the degarelix groups by day 3 (P  0.001; 
Figure 4a). At this time point, 95% of patients in the degarelix 
groups had testosterone levels 0.5 ng/mL. In contrast, no 
patients receiving leuprolide had castrate levels at day 3; indeed, 
Table 1 Percentage of patients with serum testosterone levels 
0.5 ng/mL (responders) during monthly measurements from day 28 
through to day 364 in phase ii and iii degarelix studies36–38,58
n Responders % 95% CI
Phase II European study
Degarelix 200/80 mg 28 17 61 41–78
Degarelix 200/120 mg 25 21 84 64–95
Degarelix 200/160 mg 27 26 96 81–100
Degarelix 240/80 mg 30 27 90 73–98
Degarelix 240/120 mg 30 27 90 73–98
Degarelix 240/160 mg 25 23 92 74–99
Phase II North American study
Degarelix 200/60 mg 45 42 86 73–94
Degarelix 200/80 mg 42 41 98 87–100
Phase III study
Degarelix 240/160 mg 202 199 98.3 95–99
Degarelix 240/80 mg 207 202 97.2 94–99
Leuprolide 7.5 mg 201 194 96.4 93–98
Reproduced with permission from Anderson J. Degarelix: a novel gonadotropin-
releasing hormone blocker for the treatment of prostate cancer. Future Oncol. 2009; 
5(4):433–443.58 Copyright © 2009 Future Medicine Ltd.
Abbreviation: CI, confidence interval.Cancer Management and Research 2010:2 46
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patients in this group showed a median increase in testosterone 
of 65% compared with baseline levels at this time point and 
median levels were 0.5 ng/mL until day 28. Both degarelix 
doses were as effective as leuprolide at suppressing testosterone 
levels from day 28 to study end (Figure 4b). No patient receiv-
ing degarelix experienced testosterone surge (15% increase 
in testosterone level vs baseline during the first 2 weeks) or 
microsurges (testosterone increase 0.25 ng/mL on days 
255 or 259, 3 or 7 days after the ninth injection). In contrast, 
144 patients (81%) in the leuprolide group experienced a 
testosterone surge, including 17 of the 23 patients (74%) who 
received concomitant bicalutamide. Eight leuprolide patients 
(4%) had microsurges, including four patients (2%) whose 
testosterone increased 0.5 ng/mL at the time points evaluated. 
Overall, patients in the leuprolide group showed a significant 
mean 0.05 ng/mL increase (P  0.001) in testosterone levels 
on days 255/259 compared with day 252, whereas patients 
in the degarelix group showed a slight decrease.
In the degarelix groups, median LH and FSH levels 
decreased rapidly and remained suppressed until the end of the 
study, whereas LH and FSH levels showed an initial increase 
for patients in the leuprolide group, and FSH levels did not 
fall to the same extent as they did in the degarelix arms. In 
line with the testosterone results, PSA levels also declined 
more rapidly in the degarelix 240/80 and 240/160 mg arms, 
and at days 14 (64% and 65% vs 18%) and 28 (85% and 
83% vs 68%), significantly greater suppression was observed 
compared with leuprolide (P  0.001; Figure 5a). Beyond 
day 28, PSA levels remained effectively suppressed in all 
treatment groups until the end of the 1-year study (Figure 5b). 
Overall, PSA failure (a PSA increase of 50% from nadir 
and 5ng/mL on two consecutive occasions at least 2 weeks 
apart) occurred in 8.9% of patients in the degarelix 240/80 mg 
group, 14.2% of those in the degarelix 240/160 mg group, 
and 14.1% of those in the leuprolide 7.5 mg group.38 
In a subsequent analysis of PSA progression-free survival, 
a statistically lower (P = 0.0495; log-rank test) risk of PSA 
failure or death was found for patients randomized to degarelix 
240/80 mg compared with patients randomized to leuprolide 
(ITT population).39 Overall survival at 1 year did not differ 
significantly between degarelix 240/80 mg (probability of 
death by Day 364: 2.6%; 95% CI 1.1–6.2) and leuprolide 
groups (4.9%; 95% CI 2.6–9.3).
Post-hoc subgroup analyses
Exploratory post-hoc subgroup analyses assessing the impact 
of baseline testosterone, disease stage and PSA level on 
activity were subsequently performed on data from the CS21 
trial for the degarelix 240/80 mg group (the approved dose) 
versus the leuprolide group only. The effects of both treat-
ments on total serum alkaline phosphatase (S-ALP) levels 
were also investigated. S-ALP is a recognized marker of 
metastatic bone disease in patients with prostate cancer.40 
In both treatment arms, higher baseline testosterone led to 
slower achievement of castrate testosterone levels; however, 
achievement of castrate levels occurred significantly faster 
with degarelix than with leuprolide for all testosterone sub-
groups.41 Reduction in PSA levels was also significantly faster 
with degarelix than leuprolide in all testosterone subgroups 
(P  0.0001). In the degarelix group, a rapid reduction in 
PSA began on day 1, irrespective of baseline testosterone 
level. In contrast, there was a small increase in PSA on 
days 3 and 7 in the leuprolide group, which was somewhat 
larger in the subgroup of patients with baseline testosterone 
5 ng/mL where the subsequent fall in PSA was also the 
slowest. In this subgroup of patients, the same level of PSA 
suppression was achieved for those receiving leuprolide and 
degarelix, but only after a delay of approximately 2 months 
in the leuprolide group.41
In additional analyses of the PSA data, it was found that 
PSA failures occurred mainly in patients with metastatic 
disease at baseline or PSA levels 50 ng/mL; no PSA 
failures occurred in those with baseline PSA  20 ng/mL.39 
Patients with metastatic disease or PSA levels  20 ng/mL 
at baseline experienced numerically fewer PSA failures with 
degarelix compared with leuprolide. Patients with metastatic 
disease or those with PSA levels 50 ng/mL at baseline 
also experienced greater reductions in S-ALP levels with 
degarelix than leuprolide.42 Patients in the degarelix group 
maintained S-ALP suppression throughout the 1-year study 
and did not display signs of therapy failure, as indicated by 
the late rises in S-ALP levels that were observed in patients 
receiving leuprolide.
Safety and tolerability data
In the CS21 trial, both degarelix and leuprolide were well 
tolerated, with most adverse events being mild or moderate 
in intensity.38 The most common adverse events observed 
during degarelix treatment were related to the known effects 
of androgen deprivation (hot flashes, weight increases) or the 
mode of administration (injection-site reactions; Table 2). 
There was a significantly higher incidence of injection-site 
reactions and chills with subcutaneous degarelix treatment 
than with the intramuscular leuprolide injection (40% vs 
1%; P  0.001). Injection-site events occurred predomi-
nantly after the first dose, with their incidence declining Cancer Management and Research 2010:2 47
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during maintenance treatment. Overall, 33% of 409 starter 
dose injections and 4% of 2244 and 2208 maintenance dose 
injections (240/80 and 240/160 mg groups, respectively) 
were associated with injection-site events. Only five patients 
(1%) receiving degarelix discontinued treatment due to an 
injection-site reaction. Significantly more degarelix patients 
experienced chills (4% vs 0%; P  0.01), whereas the 
incidence of disease-related adverse events such as arthralgia 
(4% vs 9%; P  0.05) and urinary tract infection (3% vs 9%; 
P  0.01) were significantly higher with leuprolide. In an 
exploratory analysis of tolerability data, musculoskeletal and 
connective tissue disorders were found to be more common 
in patients receiving leuprolide than degarelix, irrespective of 
disease stage.43 Disease-related symptoms such as arthralgia 
and back pain occurred more frequently in leuprolide patients 
with metastatic disease than in degarelix patients with meta-
static disease.
As observed in the phase II dose-finding studies, no 
immediate-onset systemic allergic reactions were reported 
during degarelix treatment.38 A similar proportion of patients 
in each group also experienced alanine aminotransferase/
aspartate aminotransferase changes, and there were no 
0
−60
−100
A
9
7
8
6
5
4
3
2
1
0
0 28 56 84 112 140 168 196
Time (days)
T
e
s
t
o
s
t
e
r
o
n
e
 
(
n
g
/
m
L
)
224 252 280 308 336 364
Degarelix 240/80 mg
Degarelix 240/160 mg
Leuprolide 7.5 mg
B
100
80
60
40
*
20
−20
−40
−80
0 1 3 7 14
Degarelix 240/160 mg
Leuprolide 7.5 mg
Time (days)
M
e
d
i
a
n
 
c
h
a
n
g
e
 
i
n
 
t
e
s
t
o
s
t
e
r
o
n
e
 
(
%
)
21 28
Degarelix 240/80 mg
Figure 4 Median testosterone levels with degarelix and leuprolide. Panel A depicts the first month of treatment; Panel B shows data from across the 1-year treatment 
period.38 Reproduced with permission from Klotz L, Boccon-Gibod L, Shore ND, et al.   The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, 
parallel-group phase iii study in patients with prostate cancer. BJU Int. 2008;102(11):1531–1538.38 Copyright © 2008 Blackwell Publishing Ltd.
*P  0.001 degarelix (both doses) versus leuprolide.Cancer Management and Research 2010:2 48
Van Poppel Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
statistically significant differences between groups in vital 
signs, body weight or QT interval.
Efficacy and safety conclusions from the phase III trial
Data from this pivotal phase III trial demonstrated that 
degarelix was an effective and well-tolerated treatment for 
patients requiring ADT for prostate cancer. Both degarelix 
doses (240/80 and 240/160 mg) were as effective as leup-
rolide in terms of treatment response. Due to its immediate 
onset of action, FSH, LH, testosterone, and PSA levels fell 
more rapidly with degarelix than with leuprolide. Unlike the 
GnRH agonist leuprolide, degarelix did not induce a surge 
(or microsurges) in testosterone and therefore there is no 
requirement for concomitant antiandrogen flare protection. 
The safety profile of degarelix, although displaying hor-
monal side effects in line with ADT, differed from that of 
leuprolide, mainly with respect to disease-related events. 
The higher incidence of injection-site events with degarelix 
predominantly occurred after the first injection and may be 
due to the mode of administration and the injection volume. 
Based on the results of this trial, degarelix 240/80 mg was 
approved in December 2008 by the FDA for the treatment of 
patients in the USA with advanced prostate cancer. This was 
followed in February 2009 by EMEA approval of the same 
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degarelix dose for the treatment of adult male patients with 
advanced hormone-dependent prostate cancer.
Patient-focused perspectives
Because of their mode of action, all hormonal therapies are 
associated with side effects that can affect physical, sexual 
and psychological functioning of men with prostate cancer 
and may have an adverse impact on a patient’s quality of life. 
While it remains the “gold standard” ADT, orchiectomy is 
irreversible and associated with psychological drawbacks, 
and has therefore now largely been replaced by medical 
castration, as patients generally prefer this option.44 GnRH 
agonists are currently the most commonly used form of 
medical ADT, as treatment with these agents is associated 
with improved quality of life compared with orchiectomy.44 
Nonetheless, the clinical flare associated with GnRH agonists 
can worsen disease symptoms12 and deleteriously impact 
upon the quality of life of some patients with advanced 
disease. Co-administration of antiandrogens may reduce or 
eliminate flare, but is associated with an additional side effect 
burden and a higher cost.
Sexual dysfunction (eg, loss of libido and erectile 
dysfunction) is a common consequence of all types of 
prostate cancer therapy.45,46 Erectile dysfunction can be 
effectively treated in many men with the use of phosphodi-
esterase 5 inhibitors such as sildenafil or tadalafil.46 There is 
also much interest in the use of intermittent ADT regimens 
in prostate cancer, as this can reduce the incidence of sexual 
side effects during off-treatment phases, thereby improving 
quality of life. This type of treatment may be particularly suit-
able for younger patients with less aggressive disease.47 Many 
clinical trials are currently assessing the efficacy and safety 
of intermittent ADT, including several studies assessing the 
potential role of degarelix 240/80 mg in such regimens.
Hot flashes are another common side effect of hormonal 
therapy, being experienced by most men undergoing ADT.46 
These can be quite debilitating and may have a substantial 
impact on quality of life of some men. Transdermal estrogen48 
Table 2 incidence and intensity of adverse events during degarelix and leuprolide treatment (incidence of 5% in any group)
Degarelix 240/80 mg Degarelix 240/160 mg Degarelix pooled Leuprolide 7.5 mg
iTT analysis set, n 207 202 409 201
Any adverse event, n (%) 163 (79) 167 (83) 330 (81) 156 (78)
  injection-site reactionsa 73 (35) 89 (44) 162 (40) 1 (1)***
  Hot flashes 53 (26) 52 (26) 105 (26) 43 (21)
  ALT increaseb 20 (10) 17 (8) 37 (9) 11 (5)
  weight increase 18 (9) 22 (11) 40 (10) 24 (12)
  Back pain 12 (6) 12 (6) 24 (6) 17 (8)
  Hypertension 12 (6) 14 (7) 26 (6) 8 (4)
  AST increasec 10 (5) 11 (5) 21 (5) 6 (3)
  Arthralgia 11 (5) 6 (3) 17 (4) 18 (9)*
  Urinary tract infection 10 (5) 3 (1) 13 (3) 18 (9)**
  Fatigue 7 (3) 13 (6) 20 (5) 13 (6)
  Hypercholesterolemia 7 (3) 12 (6) 19 (5) 5 (2)
  Chills 7 (3) 11 (5) 18 (4) 0**
  Constipation 6 (3) 11 (5) 17 (4) 10 (5)
intensity, n (%)
  Mild 138 (67) 145 (72) 283 (69) 138 (69)
  Moderate 113 (55) 112 (55) 225 (55) 101 (50)
  Severe 32 (15) 36 (18) 68 (17) 26 (13)
  Life-threatening 1 (1) 2 (1) 3 (1) 5 (2)
  Deathd 5 (2) 5 (2) 10 (2) 9 (4)
ainjection-site reactions include injection-site pain, erythema, swelling, induration, and nodule.
bOverall, 28 (7%) degarelix patients and 12 (6%) leuprolide patients had ALT increases 3 × the upper limit of normal (ULN).
cOverall, 16 (4%) of degarelix patients and 9 (4%) leuprolide patients had AST increases 3 × the ULN.
dNone of the deaths were considered related to treatment. Statistically significant differences between the pooled degarelix and leuprolide groups are indicated.
*P  0.05, **P  0.01, ***P  0.001.
Reproduced with permission from Klotz L, Boccon-Gibod L, Shore ND, et al.   The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-
group phase iii study in patients with prostate cancer. BJU Int. 2008;102(11):1531–1538.38 Copyright © 2008 Blackwell Publishing Ltd.
Abbreviations:   ALT, alanine aminotransferase;    AST, aspartate aminotransferase.Cancer Management and Research 2010:2 50
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or megestrol acetate49 can improve hot flashes, but are 
associated with gynecomastia and breast/nipple pain and 
sometimes also weight gain. Antidepressants such as par-
oxetine and venlafaxine have been shown to be effective in 
reducing hot flashes in women with breast cancer, and several 
small studies have suggested that these agents may also be 
beneficial in men with prostate cancer.50,51 As depression and 
emotional lability can also be a consequence of hormonal 
therapy,45 antidepressants may also have other positive effects 
on the patient. Gynecomastia and breast pain/tenderness occur 
commonly in men undergoing antiandrogen therapy and 
are also associated to a lesser extent with orchiectomy and 
GnRH agonist treatment.46 Prophylactic breast irradiation52 
or tamoxifen treatment53 can be effective in reducing the 
incidence and severity of breast pain and gynecomastia, but 
are both associated with an additional side-effect burden.
ADT increases markers of bone turnover, and several 
reports have demonstrated that ADT with GnRH receptor 
agonists results in a progressive decrease in bone mineral 
density, with the risk of fracture and/or development of 
osteoporosis increasing with duration of treatment.46 Patients 
most at risk of adverse skeletal effects appear to be those with 
osteopenia at the start of treatment.45 Studies on the skeletal 
consequences of treatment with GnRH receptor blockers such 
as degarelix are currently lacking, although initial analyses 
of the effect of degarelix on S-ALP levels suggest improved 
suppression with this agent compared with leuprolide.42 
Increased S-ALP levels can also reflect bone metastases 
progression54 and therefore improved S-ALP suppression 
(as well as fewer PSA failure events) may be suggestive 
of better disease control with degarelix. Various agents are 
available for preventing bone loss in prostate cancer patients 
undergoing ADT, including bisphosphonates such as pami-
dronate and zoledronic acid.55,56 Lifestyle changes such as 
stopping smoking and increased resistance weight training 
in addition to calcium and vitamin D supplementation may 
also be helpful.45,46 GnRH receptor agonist treatment also 
results in body composition changes that are accompanied 
by adverse metabolic consequences such as increased plasma 
cholesterol, triglycerides, glucose and insulin levels, which in 
turn increase risk of cardiovascular disease and diabetes.46
Regular patient follow-up may permit early diagnosis 
and treatment of any treatment-emergent side effects and 
may therefore also improve outcomes. The monthly injection 
schedule of degarelix is convenient and also enables the 
patient to receive regular contact and support from their 
healthcare provider. This has been shown to be especially 
important during the early stages of treatment and may also 
positively contribute to the patient’s coping strategies and 
quality of life.57 Less regular contact may be preferable to 
patients later in their treatment course, when any emergent 
adverse events are already being effectively managed; stud-
ies assessing the efficacy and tolerability of a degarelix 
3-monthly dosing schedule are currently ongoing.
As prostate cancer is more common in older men, patients 
often have and are being treated for comorbid conditions in 
addition to receiving ADT. As well as making it difficult to 
assess any quality-of-life changes specifically associated with 
ADT, this could potentially complicate their management. 
Therefore, the potential for any drug–drug interactions also 
needs to be examined before initiating therapy. Preclinical 
studies suggest that degarelix has a mild pharmacokinetic 
interaction profile and is therefore unlikely to be the subject 
or cause of clinically significant drug–drug interactions.29
Summary and conclusions
Orchiectomy is unacceptable to many prostate cancer patients, 
and so medical castration using GnRH receptor agonists now 
provides the mainstay of ADT for prostate cancer. The recently 
approved GnRH receptor blocker, degarelix, is as effective and 
well-tolerated as GnRH agonists but has the advantage of an 
immediate onset of action and faster testosterone and PSA 
suppression, without a surge or microsurges. The pharmaco-
logical effects of degarelix therefore more closely resemble 
those of orchiectomy. Although generally more acceptable 
to patients than orchiectomy, all forms of medical castration 
are associated with adverse events that may impact upon a 
patient’s quality of life. However, with appropriate follow-up 
and treatment, many of these adverse events can be overcome. 
In summary, degarelix is an effective and well-tolerated agent 
that provides a useful addition to the hormonal armamentarium 
for prostate cancer, offering patients with hormone-sensitive 
advanced disease a valuable alternative treatment option.
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